Phase II Trial of Vorinostat Plus Tacrolimus & Mycophenolate to Prevent Graft Versus Host Disease Following Reduced Intensity Conditioning Related Donor Allogeneic Transplant

Inclusion Criteria:

- Have a 7/8 or 8/8 HLA A, B, C and DR, HLA-matched related donor willing and able to
donate allogeneic stem cells.

- For patients with multiple myeloma, CLL, and lymphoma: must be in CR, PR, or stable
disease.

- For MDS, acute leukemia or CML: must have <20% blasts on marrow exam.

- For all other diseases: must have non-refractory disease.

and meet at least ONE of the next three criteria:

- Any patient ≥ 18 years of age with a hematological malignancy and not considered a
candidate for allogeneic myeloablative transplant due to illness and/or age (≥55
years).

- Any patient ≥ 18 years of age who has relapsed following prior autologous or
allogeneic transplant for a hematologic malignancy.

- Any patient ≥ 18 years of age diagnosed with a hematological malignancy for which
reduced intensity transplant is institutionally preferred over myeloablative
transplant (eg, chronic lymphocytic leukemia).

Exclusion Criteria:

- Less than 18 years of age.

- Currently taking any HDAC inhibitors, or have taken an HDAC inhibitor within 30 days
of the trial.

- Positive serum tests for HIV, HTLV1 / HTLV2.

- Detectable hepatitis B virus (HBV), hepatitis C (HCV) or Epstein-Barr (EBV).

- Pregnancy.

- One or more of the following organ system function criteria

- Cardiac: Ejection fraction ≤ 40%

- Renal: Estimated or actual GFR ≤ 40 ml/min (corrected for BSA)

- Pulmonary: FEV1, FVC, or DLCO ≤ 40% predicted

- Hepatic: Total bilirubin ≥3 mg% and AST/ALT >5 x institutional normal for age

- Karnofsky score ≤50 (Requires considerable assistance and frequent medical
care).

- Persistent invasive infections not controlled by antimicrobial medication.

- Any physical or psychological condition that, in the opinion of the investigator,
would pose unacceptable risk to the patient.